Objective To compare the efficacy and safety of two antiplatelet regimens, ticlopidine alone (200 mg daily) and ticlopidine (100 mg daily) plus aspirin (81 mg daily), in patients with ischemic stroke from the Tokai district of Japan.
Introduction
Antiplatelet agents are effective for the prevention of recurrent cerebral infarction and transient ischemic attacks (TIA). While aspirin and ticlopidine are widely prescribed in Japan, serious side effects of ticlopidine such as hepatotoxicity, agranulocytosis and thrombotic thrombocytopenic prupura have been reported. Thus, clopidogrel, a newand safer thienopyridine derivative whichis the same class as ticlopidine, is generally administered in Western countries.
Aspirin inhibits platelet aggregation by blocking platelet cyclo-oxygenase, while ticlopidine exerts its antiplatelet activity by inhibiting platelet ADP receptors (1, 2) . The efficacy of aspirin has been demonstrated in several clinical studies (3) (4) (5) (6) , but the optimum dose remains controversial.
The efficacy of ticlopidine has also been demonstrated in several studies (3, (7) (8) (9) . These drugs are usually administered as monotherapy, but a combination of aspirin and ticlopidine is also used with the aim of achieving a more potent antiplatelet effect (10) (11) (12) (13) . However, such combined therapy might increase the risk of major bleeding. Therefore, there is a need to determine the most appropriate doses. In a study on cerebral infarction and TIA, Uchiyama and colleagues (14) compared low-dose combination therapy with aspirin (81 mg/day) plus ticlopidine (100 mg/day) versus monotherapy with aspirin (300 mg/day) or ticlopidine (200 mg/day). They reported that combined treatment with aspirin and ticlopidine, which aims to inhibit all of the platelet aggregation pathways via ADP, arachidonic acid, and plateletactivating factor, might be a potent antiplatelet strategy. However, the combined treatment with aspirin and ticlopidine shows prolongation of bleeding time and more bleeding complications, a well-designed prospective study should be implemented to evaluate the usefulness of the combination therapy.
In this long-term treatment study, patients with cerebral infarction or TIA were randomized to monotherapy with a normal dose of 200 mgof ticlopidine per day or to combination therapy with both lower doses of 100 mgof ticlopidine and 81 mgof aspirin per day. The primary endpoint was the occurrence of vascular events such as cerebrovascular diseases and bleeding complications. Due to the small subject number in this study the results may not be conclusive but they are supportive.
Subjects and Methods

Study design
Between April 1992 and December 1995, patients with cerebral infarction or TIA who were treated at hospitals in the Tokai district of Japan were randomly allocated to either the ticlopidine monotherapy group (200 mg/day) or to a combination therapy group that received low-dose ticlopidine (100 mg per day) plus low-dose aspirin (81 mg/day). The subjects were followed up for an average of 1.59 years (maximum: 3 years), during which period the safety of each therapy was investigated, as well as the incidence of cerebral infarction, TIA, myocardial infarction, and other vascular events.
Pa tien ts
The subjects were patients whohad suffered from noncardiogenic cerebral infarction within the previous 1-6 months or had experienced one or more episodes of TIA within the previous 3 months. Informed consent was obtained from each patient.
Patients who had a history of cerebral hemorrhage or cardiogenic cerebral infarction, or any contraindications to treatment with ticlopidine or aspirin were excluded from the study. Also excluded were patients who had severe hepatic or renal dysfunction, a bleeding tendency, a history of hypersensitivity to ticlopidine, aspirin, or salicylic acid preparations, or previous treatment with ticlopidine or aspirin after cerebral infarction or TIA. Pregnant or breast-feeding women werealso excluded.
Outcomes
The endpoints of this study were the recurrence of cerebrovascular events and the occurrence of myocardial infarction or other vascular events. The following combinations of these events were selected as outcomes for evaluation: recurrent cerebral infarction, cerebral hemorrhage, recurrent cerebral infarction, TIA, or cerebral hemorrhage, and recurrent cerebral infarction, TIA, cerebral hemorrhage, and myocardial infarction or other vascular events.
Statistical analysis
The baseline characteristics of the patients were analyzed by the %2 test and the Wilcoxon rank-sum test, and the recurrence rate or incidence of cerebrovascular events, myocardial infarction, or other vascular events, as well as data on adverse reactions, were analyzed by the %2test. The event-free rate for cerebrovascular events, myocardial infarction, and other vascular events was comparedbetweenthe two groups by Kaplan-Meier analysis and the log-rank test. The level of significance was set at p<0.05 (two-tailed).
Results
Enrollment of patients
Between April 1992 and December 1995, 276 patients were enrolled at 25 institutions participating in this trial.
Seven patients were excluded from the study, comprising 3 patients who did not take the study drug at all despite being instructed to do so, 2 patients who were not actually treated with the study drug after enrollment, and 1 patient who was treated outside the study period. As a result, 270 patients (138 from the TIC group and 132 from the TIC+ASA group) were eligible for analysis ( Fig. 1 ).
Clinical profile
The baseline characteristics of the 270 subjects are shown in Table 1 ischemic heart disease (9.4% and 8.3%), and hyperlipidemia (8.0% and 12.1%). There were no significant differences between the two groups with respect to these complications. Arrhythmia (not confirmed to be atrial fibrillation or another type) was detected in five patients (3.6%) of the TIC group and three patients (2.3%) of the TIC+ASAgroup, but none of them had a newstroke. The subtypes of cerebral infarction were determined on the basis of the clinical features and the site of the infarct focus, and were well matched between the 2 groups.
Outcome events 
TIA, myocardial infarction, or other vascular events) during the follow-up period is shown in (Table 3) . The difference between the two groups was not statistically significant. The event-free rates for each group calculated by Kaplan-Meier analysis are shown in Fig. 2 .
The log-rank test showed no significant difference between the two groups (p=0.5003).
Stratified analysis of events
The events that occurred in the TIC group consisted of cerebral infarction in 7 patients, TIA in 4 patients, myocardial infarction in 2 patients, and arteriosclerosis obliterans (ASO) in 1 patient. The events occurring in the TIC+ASA group consisted of cerebral infarction in 7 patients, cerebral hemorrhage in 2 patients, TIA in 3 patients, and ASOin 1 patient. Whilecomparisonof the annual incidence of events showed no significant differences between the two groups, cerebral hemorrhage was reported in only two patients from the TIC+ASA group (Table 4) .
Safety
During the study period, adverse reactions were reported in 15 patients (10.9%) of the TIC group and 17 patients (12.9%) of the TIC+ASA group, with the difference between the two groups not being significant (p=0.610). A list of the adverse reactions is shown in Table 5 . Serious adverse reactions included leukopenia in 1 patient of the TIC group, as well as gastric ulcer, nausea, and thrombocytopenia in one each of the TIC+ASAgroup (a total of 3 patients).
Follow-up of these adverse events showed that nausea (TIC+ASA group) persisted, but the other symptoms subsided or were relieved. Gastrointestinal symptomswere reported in 7 patients of the TIC+ASAgroup, and vomiting was reported in 1 patient of the TIC group. Leukopenia occurred in a 58-year-old female patient with a WBCof 4,000/mm3 before administration. The WBCdecreased to 3,300/mm3 during the 4th week of ticlopidine therapy and administration was immediately discontinued. The WBCrecovered to 4,000/mm3 after 4 weeks of follow-up, so ticlopidine therapy was resumed. The WBCdid not change thereafter and administration was continued. Thrombocytopenia occurred in a 63-year-old male patient with a platelet count of 27.6x107mm3before administration. During the 4th week after the start of coadministration of ticlopidine and aspirin, the platelet count decreased to 4.9x lOVmm3, and ticlopidine administration was immediately discontinued. The patient was followed up and the platelet count recovered to 1 1.9x107mm3at 8 weeks after the discontinuation of ticlopidine therapy. Neither this patient nor any of the other patients developed thrombotic thrombocytopenic purpura.
Discussion
In this study, the recurrence of cerebrovascular events and the occurrence of myocardial infarction and other vascular events were assessed as a combined endpoint. Fourteen patients (10.1%) of the TIC group and 13 patients (9.9%) of the TIC+ASA group reached the endpoint, with no significant difference being seen between the two groups (p=0.935). Kaplan-Meier analysis of the event reduction rate (i.e., the decrease in the occurrence of cerebral infarction, TIA, myocardial infarction, cerebral hemorrhage, and other vascular events) revealed no significant difference between the two groups (p=0.5003, log-rank test). Comparison of the annual incidence of events showed that it was 5.7/100 person-years in the TIC group and 7.1/100 person-years in the TIC+ASAgroup. The type of events that occurred generally showeda similar pattern in both groups. However, despite the fact that there was no significant difference in the annual incidence of vascular events, it was noteworthy that cerebral hemorrhage occurred only in the TIC+ASA group. Cerebral hemorrhage occurred in 2 men aged 82 and 68 years with a history of cerebral infarction. The 82-year-old patient also had a history of severe hypertension, which had been well controlled. Moderate bleeding into the right putamen was observed at 2 years and 7 months after the start of combination therapy, and administration was discontinued. There was a possibility that this therapy led to enlargement of the hematoma. The 68-year-old patient did not have hypertension and was followed up on combined therapy for 1 year and 6 months. Thereafter, he did not return to hospital for review. It was confirmed by telephone that cerebral hemorrhage had occurred one monthlater and he had been admitted to another hospital. According to his family, the patient had hemiplegia caused by a major cerebral hemorrhage. Uchiyama and colleagues (14) also reported that hemorrhagic complications were more frequent amongpatients receiving aspirin plus ticlopidine compared with those receiving aspirin alone or ticlopidine alone. The serious adverse reactions noted in our study consisted of leukopenia in 1 patient from the TIC group, as well as gastric ulcer, nausea, and thrombocytopenia in 1 patient each from the TIC+ASA group. Amongthe serious adverse reactions experienced by patients receiving combined therapy, it seems likely that gastric ulcer and nausea were associated with administration of aspirin, while leukopenia and thrombocytopenia were associated with administration of ticlopidine.
The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial (CURE) (15) was a randomized comparative study of the prevention of recurrent events by aspirin monotherapy or combined therapy with aspirin and clopidogrel (another thienopyridine) in 12,500 patients with acute coronary syndromeand no ST elevation. The relative risk of recurrent events was significantly lower in the combination therapy group (reduced by 20%). There were significantly more patients with major bleeding in the combination therapy group than in the monotherapy group, but there was no significant difference in episodes of life-threatening bleeding or hemorrhagic stroke (15) . Since the subjects of that study had coronary artery diseases, the results cannot be directly compared with data on the efficacy and safety of combined therapy for patients with cerebral infarction (16) . However, bleeding complications caused by antithrombotic therapy tend to be more commonin patients with cerebrovascular disease than in those with heart disease (17) .
In the present study, it is particularly noteworthy that no cerebral hemorrhage occurred in the TIC group, while it occurred in two patients from the TIC+ASAgroup. In conclusion, the present comparison of the preventive effect of ticlopidine alone (200 mg/day) with that of aspirin (81 mg/ day) plus ticlopidine (100 mg/day) on vascular events (stroke, TIA, myocardial infarction, and other vascular events) in patients with cerebral infarction or TIA showed no difference between the two treatment strategies with respect to the event rate. However,the present study population was rather small, so further exploration of this issue by a largescale clinical study is necessary. In this context, the
Management of Atherothrombosis with Clopidogrel in High-
Risk Patients (MATCH) (18) study is currently in progress.
MATCH has enrolled 7,600 patients with a high risk of cerebral infarction or TIA and complications such as previous myocardial infarction, and it aims to compare subsequent stroke and other important vascular events between clopidogrel monotherapy and combined therapy with clopidogrel and aspirin. The results of MATCH will provide further information on the efficacy and safety of combination therapy with a thienopyridine and aspirin.
